Envestnet Asset Management
MRKR icon

Envestnet Asset Management’s Marker Therapeutics MRKR Stock Holding History

Envestnet Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,141
Closed -$32K – 3317
2020
Q3 		$32K Buy
+2,141
New +$39.1K ﹤0.01% 3074

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Envestnet Asset Management's MRKR Position: Q4 2020 in Review

Envestnet Asset Management sold out of Marker Therapeutics (MRKR) in Q4 2020, closing a stake of 2,141 shares — an estimated $32K sold.

Envestnet Asset Management first reported a position in MRKR in Q3 2020 and held it in 1 quarter. The position peaked at $32K in Q3 2020. 60 funds tracked by Wall St. Rank hold MRKR as of Q4 2020.

  • Envestnet Asset Management reported no remaining Marker Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 2,141 Marker Therapeutics shares in Q4 2020, an estimated $32K.
  • Envestnet Asset Management first reported a position in Marker Therapeutics in Q3 2020 and held it in 1 quarter.
  • Envestnet Asset Management's Marker Therapeutics position peaked at $32K in Q3 2020.
  • 60 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2020.

Based on Envestnet Asset Management's 13F filing for Q4 2020, filed 2 Feb 2021.